US Patent Issued to Icahn School of Medicine at Mount Sinai on Aug. 5 for "Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis" (Dutch, American Inventors)

ALEXANDRIA, Va., Aug. 6 -- United States Patent no. 12,377,054, issued on Aug. 5, was assigned to Icahn School of Medicine at Mount Sinai (New York).

"Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis" was invented by Willem Mulder (Eindhoven, Netherlands), Jordi Ochando (New York), Zahi Fayad (Larchmont, N.Y.), Mounia Braza (New York), Raphael Duivenvoorden (Gelderland, Netherlands) and Francois Fay (New York).

According to the abstract* released by the U.S. Patent & Trademark Office: "Methods and compositions for inducing long-term tolerance by hybrid nanoparticles are provided. Compositions and formulations comprising hybrid nanoparticles with inherent affinity fo...